CME/CE

Provided by The Obesity Society and DKBmed, LLC.

Target Audience

This educational program is designed for Endocrinologists, Hepatologists, Primary Care Physicians (MDs and DOs), and Advanced Practice Providers (e.g., Nurse Practitioners (NPs) and Physician Associates (PAs) working in specialty or primary care clinics. A secondary audience also includes Pharmacists.  

Educational Objectives

  • Identify and articulate the pathophysiologic mechanisms that underlie the development and progression of MASLD.  
  • Evaluate and apply evidence-based strategies to improve detection of MASLD, MASH, and fibrosis.  
  • Analyze the natural history and clinical consequences of MASLD to differentiate disease stages and describe outcomes.  
  • Critically appraise and synthesize safety and efficacy findings from recent clinical trials of dual GLP-1/glucagon receptor agonists for MASH treatment.  

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Obesity Society and DKBmed. The Obesity Society is accredited by the ACCME to provide continuing medical education for physicians. 

Credit Designation Statement

The Obesity Society designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity. 

Request for Credit

If you wish to receive acknowledgment for completing this activity, please complete the evaluation.

Release date: December 15, 2025
Expiration date: December 14, 2026

Acknowledgement

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.